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by widespread infl ammation affecting virtually 
every organ or system in the body. The disease is 
associated with the deposition of autoantibodies 
and immune complexes, leading to tissue 
damage.6
 The exact patho-aetiology of SLE remains 
elusive. An extremely complicated and 
multifactorial interaction among various genetic 
and environmental factors is probably involved. 
Multiple genes contribute to disease susceptibility. 
The interaction of sex, hormonal milieu, and the 
hypothalamo–pituitary–adrenal axis modifi es 
this susceptibility and the clinical expression 
of the disease. Defective immune regulatory 
mechanisms, such as the clearance of apoptotic 
cells and immune complexes, are important 
contributors to the development of SLE. The loss 
of immune tolerance, increased antigenic load, 
excess T cell help, defective B cell suppression, 
and the shifting of Th1 to Th2 immune responses 
lead to B cell hyperactivity and the production of 
pathogenic autoantibodies.6-8 Prolonged periods 
of immune response to external/environmental 
factors such as UV radiation or viral infection can 
also cause immune system dysregulation.9
 Cytokines have been implicated in regulating 
disease activity and the involvement of different 
organs in SLE. T helper cells can be divided into 
different subsets depending on their cytokine 
profi le. The Th1 cells increase macrophage 
activation and produce IL-2, IFN-γ and tumor 
necrosis factor (TNF)-α. The Th2 cells stimulate 
antibody production and upregulate humoral 
immunity and allergic responses. They produce 
IL-4, IL-5, IL-6, IL-10 and IL-13. The Th3 
cells are regulatory cells that can act to induce 
immune tolerance and characteristically produce 
transforming growth factor-β, IL-4 and IL-10. The 
Th0 cells can produce cytokines of all three types. 
The pattern of cytokine production in different 
disease states may be described as a Thl, Th2, or 
Th3 response based on the cytokines produced. 
Recent experimental observations suggest a key 
role for IL-10 in the pathogenesis of SLE as it 
has a particular ability to encourage B cells to 
make antibodies.6 The pathogenesis of SLE is 
summarized diagrammatically in fi gure 1.
ABSTRACT
Leptin is a 16 kDa adipocyte-secreted hormone that 
regulates weight centrally and links nutritional status 
to neuroendocrine and immune functions. Several 
studies indicate that leptin plays an important role in 
immune responses. Leptin affects both innate and 
adaptive immunity. It can stimulate dendritic cells (DC), 
monocytes, macrophages, neutrophils and natural killer 
cells. Leptin is involved in DC maturation and survival, 
and can skew the cytokine balance of a T helper 
(Th)1 profi le. In adaptive immunity, leptin can promote 
naïve T cell survival and production of interferon-γ and 
interleukin-2, and activate Th1 cells while inhibiting 
Th2 cells. Leptin may play an important role in the 
regulation of the Th1/Th2 balance. As a survival factor, 
leptin has been shown to suppress B cell apoptosis. 
The role of leptin in the pathogenesis of systemic lupus 
erythematosus (SLE) is not fully determined yet. This 
review tries to link the role of leptin in immunity to the 
pathogenesis of SLE.
Leptin constitutes a hormone synthesized by the 
adipose tissue that binds with a receptor which is 
a member of the class I cytokine receptor family.1-
4 Leptin has been increasingly recognized as a 
cytokine-like hormone with pleiotropic actions in 
modulating immune responses. Leptin can activate 
monocytes, dendritic cells (DC), and macrophages 
and stimulate them to produce T helper (Th)1 type 
cytokines. Leptin also exerts activating effects 
on neutrophils and natural killer (NK) cells and 
stimulate their gene expressions. Importantly, 
leptin has been shown to modulate the adaptive 
immunity via enhancing T cell survival and 
stimulating their production of pro-infl ammatory 
cytokines such as interferon (IFN)-γ and 
interleukin (IL)-2. Recent evidence demonstrates 
a detrimental involvement of leptin in promoting 
the pathogenesis of various autoimmune diseases. 
In respect of its diverse functions in immunity, 
leptin has been explored as a potential target for 
therapeutic development in treating autoimmune 
diseases.5
PATHOGENESIS OF SYSTEMIC LUPUS 
ERYTHEMATOSUS
Systemic lupus erythematosus (SLE) is an 
autoimmune rheumatic disease characterized 
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STRUCTURE OF LEPTIN RECEPTOR
The discovery of leptin in 1994 completely changed the 
traditional view of white adipose tissue (WAT). Actually, WAT 
was considered for decades as only a triglyceride reservoir 
with a passive or null endocrine role. The discovery of leptin, 
followed by many other adipocyte-derived molecules, called 
adipokines, identifi es the adipose tissue as one of the main 
endocrine organs with an active and relevant role in regulating 
energy homeostasis, metabolism, as well as immune-
infl ammatory processes.10
 Leptin is derived from the Greek leptos, meaning thin. 
Leptin is a 16 kDa non-glycosylated peptide hormone 
encoded by the obese (ob) gene and mainly produced by 
adipocytes although low levels has been detected in the 
hypothalamus, pituitary, stomach, skeletal muscle, mammary 
epithelia, chondrocytes, and a variety of other tissues. Leptin 
is structurally and functionally related to the IL-6 cytokine 
family.10-12 
 The leptin receptor (Ob-R) is a cytokine receptor and 
belongs to the class I cytokine receptor family.2-4,13 The Ob-
R gene produces at least six transcripts designated Ob-Ra 
through Ob-Rf. Two of the isoforms have been described in 
only one species each, Ob-Rd in mice and Ob-Rf in rats. In 
humans, only expression of Ob-Ra, Ob-Rb and Ob-Rc mRNA 
have been reported.11 Ob-R is encoded by the diabetes (db) 
gene. The OB-R shares the highest structural similarity and 
signaling capability with those of the IL-6 type cytokine 
receptors. It contains four fi bronectin type III domains, four 
conserved cysteine residues and two cytokine-like binding 
motifs, Trp-Ser-Xaa-Trp-Ser, in the extracelullar region. The 
OB-R exists in a dimeric form even in the absence of leptin 
and is activated upon ligand binding. By alternative splicing, 
OB-R mRNA gives rise to six different isoforms that share 
identical extracellular binding domain but with cytoplasmic 
domains of different length which include one soluble form 
(OB-Re), four short forms (OB-Ra, OB-Rc, OB-Rd, and 
OB-Rf) and one long form (OB-Rb). The different isoforms 
have distinct biological activities. For example, OB-Ra is 
responsible for the transport of leptin across the blood-brain 
barrier whereas the soluble OB-Re serves as a regulator of 
circulating leptin levels. Among the six isoforms, only OB-
Rb is most capable of transducing its signaling function and 
has been shown to be of prime importance in leptin-mediated 
signaling (fi g 2).5,14 
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Figure 1   The pathogenesis of systemic lupus 
erythematosus. Multiple genes confer susceptibility 
to disease development. Interaction of sex, hormonal 
milieu, the hypothalamo–pituitary–adrenal axis, and 
defective immune regulation, such as clearance 
of apoptotic cells and immune complexes, modify 
this susceptibility. The loss of immune tolerance, 
increased antigenic load, excess T cell help, 
defective B cell suppression, and shifting of T 
helper (Th)1 to Th2 immune responses lead to 
cytokine imbalance, B cell hyperactivity, and the 
production of pathogenic autoantibodies. Finally, 
certain environmental factors are probably needed 
to precipitate the onset of the disease (adapted from 
Mok et al., 2003)7
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Figure 2   Structure and isoforms of mouse 
leptin receptor. The Ob-R gene produces 
at least six transcripts designated Ob-Ra 
through Ob-Rf. One soluble form (OB-Re), 
four short forms (OB-Ra, OB-Rc, OB-Rd, 
and OB-Rf) and one long form (OB-Rb). 
Cytokine receptor homology module 
(CRH)2 is the main binding site for leptin on 
the Ob-R. The immunoglobulin-like fold (Ig-
like) and the fi bronectin type III domain (FN 
III) domains are critically involved in Ob-R 
activation. Cytokine receptor homology 
module (CRH)2 is the main binding site for 
leptin on the Ob-R. The Ig-like and the FN 
III domains are critically involved in Ob-R 
activation (adapted from Bernotiene et al., 
2006).11 
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LEPTIN SIGNALING TRANSDUCTION PATHWAYS
Intracellularly, all six OB-R isoforms contain a highly 
conserved proline-rich box 1 (intracellular amino acid 6-
17) but only OB-Rb has an extended intracellular domain of 
approximately 300 residues. The major functions of all short 
isoforms except OB-Re are limited to leptin transportation, 
internalization, and degradation although some evidence 
suggests that they are capable of triggering certain signaling 
events. The long receptor OB-Rb, a fully functional receptor, 
does not have an intrinsic tyrosine kinase domain but its box 
1 motif recruits and binds janus kinases (JAKs). The  box 
1  motif  together  with  the  immediate surrounding amino 
acids is essential for JAK activity. The extended intracellular 
domain in the distal part of OB-Rb is required for the induction 
of signal transducers and activators of transcription (STAT) 
signaling.5
 Upon leptin binding, OB-Rb-associated JAK2 at the box 
1 motif is activated which then auto-phosphorylates its own 
tyrosine residues and phosphorylates tyrosine residues on the 
intracellular domain of the receptor (Tyr 974, Tyr 985, Tyr 
1077 and Tyr 1138) to provide docking sites for signaling 
proteins containing src homology 2 (SH2) domains (fi g 3). The 
phosphorylated tyrosine residues Tyr 1077 and Tyr 1138 bind 
to the STAT proteins which are then activated and translocated 
to the nucleus to stimulate gene transcription.5,15,16 Both Tyr 
1077 and Tyr 1138 bind to STAT5 while only Tyr 1138 
recruits STAT1 and STAT3. The other two phosphorylated 
residues Tyr 974 and Tyr 985 recruit SH2 domain-containing 
phosphatase 2 (SHP2) which activates the mitogen-activated 
protein kinase (MAPK) pathways including extracellular 
signal-regulated kinase (ERK1/2), p38 MAPK and p42/44 
MAPK pathways through interaction with the adaptor protein 
growth factor receptor-bound protein 2 (GRB2).5,17-19 The auto-
phosphorylated JAK2 at the box 1 motif can phosphorylate 
insulin receptor substrate1/2 (IRS1/2) that leads to activation 
of phosphatidylinositol 3-kinase (PI3K)/Akt and the MAPK 
pathways.5,16,20-22
 Leptin has also been shown to activate various isoforms 
of STATs including STAT1, STAT3, STAT5 and STAT6 
in a variety of cell types15,23,24 (Figure 3). Among various 
STAT proteins activated by OB-Rb, STAT3 has been most 
extensively reported to mediate effects of leptin on growth and 
function of normal and cancer cells as well as immune cells, 
primarily by inducing various gene expressions such as c-
fos, c-jun, egr-1 and activator protein-1.5,25,26 STAT3 has been 
shown to mediate the leptin signal in activating macrophages 
and in promoting the survival and activation of lymphocytes 
and peripheral mononuclear cells. Src associated in mitosis 
protein 68 (Sam68), an RNA binding protein involved 
in inhibiting cell proliferation, is tyrosinephosphorylated 
and forms a complex with activated STAT3 upon leptin 
stimulation in human peripheral blood mononuclear cells.27-29 
The phosphorylation on Sam68 leads to its dissociation from 
RNA and allows it to bind to proteins containing SH2 and SH3 
domains.30  On the other hand, STAT3 can induce activation 
of the negative-feedback regulator, suppressors of cytokine 
signaling 3 (SOCS3), which binds to the phosphorylated 
tyrosines (Tyr 985, Tyr1077 and Tyr 1138) on the receptor 
to inhibit leptin signaling.31,32 The involvement of SOCS3 in 
the negative-feedback control of leptin signaling is suggested 
to underlie the development of leptin resistance commonly 
found in obesity.17 Other proteins of the SOCS family that are 
induced by leptin include SOCS1 and SOCS2.13,33 Based on 
the complex activation network of the STAT proteins, further 
analyses on their regulation by leptin signaling in immune cells 
will merit a fuller understanding of leptin-mediated immune 
modulation. Apart from the SOCS proteins induced by STATs 
to inhibit leptin signaling, protein tyrosine phosphatase 1B 
(PTP1B) is another negative regulator localized on the surface 
of endoplasmic reticulum and acts by dephosphorylation 
of JAK2 on OB-R. Moreover, overexpression of PTP1B 
has been shown to inhibit leptin-induced SOCS3 and c-fos 
expression.5,34-36
 Leptin activates the MAPK cascade via the recruitment of 
SHP2 to OB-Rb, which then binds to GRB2 to activate further 
signaling steps including RAS, RAF and MEK1, leading to 
the activation of ERK1/2, p38 MAPK and p42/44 pathways.17-
19,37 The primary docking site for SHP2 is phosphorylated Tyr 
974 and Tyr 985.17 It has been reported that leptin can induce 
c-jun N-terminal protein kinase (JNK) via phospholipase C 
(PLC) and subsequently protein kinase C (PKC) activation.38,39 
In neutrophils, leptin activates chemotaxis via p38 MAPK 
pathway.40 Leptin also stimulates TNF-α production via p38 
and JNK MAPK pathways in LPS-stimulated kupffer cells.41 
Furthermore, leptin has been shown to activate the MAPK 
pathways to mediate anti-apoptotic effects in mononuclear 
cells.18,30,42 The MAPK pathways are essential in regulating 
a wide range of immune functions. ERK1/2 and p38 MAPK 
pathways synergistically mediate cytokine production in 
DC and participate in the chemokine production in CD40L-
stimulated macrophages.5,43,44
 The PI3K/Akt pathway represents a key signaling cascade 
which mediates effects of a wide range of ligands in a variety 
of different cell types. The typical target of PI3K, Akt, is an 
integral part of a key signaling pathway that is necessary for 
inducing immune and infl ammatory responses.26 Akt is also 
the mediator of signals from pro-infl ammatory cytokines and 
toll-like receptor ligands in a variety of immune cells. The 
PI3K/Akt pathway is the upstream regulator for a number of 
effectors including the antiapoptotic transcription factor NF-
κB. Akt inhibits its downstream target pro-apoptotic forkhead 
transcription factor FOXO1 or FKHR-L1, which functions to 
induce the expression of Bim, a pro-apoptotic member of the 
Bcl-2 family proteins.5
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Figure 3   Signaling pathways activated by leptin. Only the long form of the leptin receptor (OBRb) can signal intracellularly. After binding leptin, 
OBRb-associated Janus-family tyrosine kinase 2 (JAK2) becomes activated by auto- or cross-phosphorylation and tyrosine phosphorylates the 
cytoplasmic domain of the receptor. Four of the phosphorylated tyrosine residues function as docking sites for cytoplasmic adaptors such as signal 
transducer and activator of transcription (STAT) factors, particularly STAT3. After subsequent dimerization, STAT3 translocates to the nucleus 
and induces the expression of suppressor of cytokine signalling 3 (SOCS3) and other genes such as c-fos, c-jun, egr-1, activator protein-1 (AP-
1). SOCS3 takes part in a feedback loop that inhibits leptin signalling by binding to phosphorylated tyrosines. SRC homology 2 (SH2) domain-
containing phosphatase 2 (SHP2) is recruited to Tyr985 and Tyr974 and activates extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 
mitogen-activated protein kinase (MAPK) pathways through the adaptor protein growth factor receptor-bound protein 2 (GRB2). Ultimately after 
leptin binding, JAK2 can induce phosphorylation of the insulin receptor substrate 1/2 (IRS1/2) proteins that are responsible for the activation of 
phosphatidylinositol 3-kinase (PI3K). Phosphotyrosine phosphatase 1B (PTP1B), which is localized on the surface of the endoplasmic reticulum, is 
involved in negative regulation of OBRb signalling through the dephosphorylation of JAK2. Activation of NF-κB by leptin binding has been shown to 
induce Bcl-2 and Bcl-XL expressions (adapted from Lam et al., 2007).5
Review
8 Indonesian Journal of Rheumatology 2009; Vol 01
EFFECTS OF LEPTIN ON INNATE IMMUNE RESPONSES
The role of leptin in innate immunity has been demonstrated 
by a wide range of leptin actions on antigen-presenting 
cells (APCs), NK cells, and neutrophils.5 Congenital leptin 
defi ciency in human displayed dysfunctional immune function 
such as an increased incidence of infection-related death 
during childhood  and leptin therapy has been shown to correct 
multiple immune abnormalities in these patients.45,46  Both db/
db and ob/ob mice exhibit defective cell-mediated immunity 
and lymphoid atrophy with enhanced susceptibility to infection 
and injuries.47 Peritoneal macrophages in ob/ob mice display 
impaired phagocytic capacity which rendered them unable to 
clear bacterial infection.48 The fi ndings that leptin expression 
can be induced rapidly by infl ammatory stimuli such as LPS, 
IL-1, and TNF-α during the acute phase of immune response 
indicate a role for leptin acting as a mediator in regulating 
infl ammatory activities.48,49 Several studies have shown that 
leptin signaling participates in innate immunity by promoting 
the maturation and survival of DC. In the absence of leptin 
signaling, DC display a Th2-biased cytokine profi le while 
exogenous leptin treatment skewed the cytokine balance of 
normal DC towards a Th1 profi le.5,50,51 The altered Th1:Th2 
cytokine balance is associated with a corresponding change 
in the immuno-stimulatory capacity on T cells. In monocytes 
and macrophages, leptin has been shown to stimulate 
proliferation and phagocytosis, together with production of 
pro-infl ammatory cytokines.42 In macrophages, leptin can 
induce production of factors involved in regulating immune 
responses such as nitric oxide, leukotriene B4, cholesterol 
acyl-transferases-1 and cyclooxygenase 2.49,52-54
 Leptin can stimulate DC, monocytes, macrophages, 
neutrophils, and NK cells. Leptin is involved in DC maturation 
and survival, and can skew the cytokine balance of a Th1 
profi le. In monocytes and macrophages, leptin has been shown 
to stimulate proliferation and phagocytosis, together with 
production of pro-infl ammatory cytokines.5 Leptin modulates 
the activity and function of neutrophils by increasing 
chemotaxis and the secretion of oxygen radicals (such as 
hydrogen peroxide, H2O2 , and superoxide, O2
-) through 
direct and indirect mechanisms.55,56 In humans, the action of 
leptin seems to be mediated by TNF secreted by monocytes.57 
Leptin increases phagocytosis by monocytes/macrophages 
and enhances the secretion of pro-infl ammatory mediators 
of the acute-phase response and the expression of adhesion 
molecules.42,58 On NK cells, leptin increases cytotoxic ability 
and the secretion of perforin and IL-2.55,59 
EFFECTS OF LEPTIN ON ADAPTIVE IMMUNE RESPONSES
The functions of leptin in stimulating the pro-infl ammatory 
cytokine production involved in innate immune responses can 
indirectly modulate the adaptive immunity. Early studies on 
db/db mice revealed that the development and maturation of 
both T and B cells are severely affected with reduced numbers 
of lymphocytes in peripheral lymphoid organs.5,60 The immune 
abnormalities in immune responses are observed in ob/ob and 
db/db mice as well as T cells in the ob/ob mice indicating 
a protective role of leptin in enhancing T cell survival. In a 
recent study, treatment with pharmacologic doses of leptin 
in the ob/ob mice stimulates thymopoiesis even in the LPS-
induced thymic atrophy.61 Furthermore, leptin has been shown 
to promote the survival of both T and B lymphocytes by 
suppressing Fas-mediated apoptosis which may result from its 
induction of the anti-apoptotic proteins including Bcl-2 and 
Bcl-XL.50,62,63  Leptin also increases the production of a variety 
of proinfl ammatory cytokines such as IFN-γ and IL-2 in T 
lymphocytes and modulates the immune response towards the 
Th1 phenotype by stimulating CD4 in mice with starvation-
induced leptin defi ciency.5
 Thymic atrophy induced upon starvation was prevented 
by leptin replacement, and leptin also protected thymocyte 
apoptosis by maintaining thymic maturation of the double 
positive CD4+CD8+ T lymphocyte proliferation with 
activation of STAT3 and its DNA binding activity.5,23,58 In Th1 
cells, leptin increases their TNF-α and IFN-γ production and 
IgG2a switching by B cells. In contrast, leptin exerts inhibitory 
effects on Th2 cells by reducing IgG1 switching. Consistently, 
CD4+ T cells from db/db mice showed impaired proliferative 
capacity.27 Notably, leptin can modulate specifi c aspects of T 
cell function with differential effects on distinct subpopulations 
of lymphocytes, as demonstrated by the fi ndings that leptin 
can stimulate proliferation of CD4+CD45RA+ naїve T cells 
but inhibit anti-CD3-driven proliferation of CD4+CD45RO+ 
memory T cells while stimulating their production of IFN-γ.64 
These studies indicate the diverse actions of leptin in regulating 
immune homeostasis. Although the immunomodulatory role of 
leptin in immunity has become increasingly evident, the other 
major function of leptin as an endocrine hormone to regulate 
energy storage and metabolism has added complexity in 
ascertaining the leptin effects either in immune modulation or 
in metabolic functions. This requires cautious interpretations 
of the observed immune defi cits in the ob/ob and db/db mice, 
as hyperglycemic and insulin resistant conditions that occur 
during their early adulthood can affect the immune system 
indirectly.5
 Leptin is essential for thymic homeostasis by its anti-
apoptotic functions and maintenance of thymic maturation.5,65 
Leptin can promote naїve T cell survival and production of 
IFN-γ and IL-2, and activate Th1 cells while inhibiting Th2 
cells.5,66 On Th1 cells, it increases their TNF-α and IFN-
γ production, and IgG2a switching by B cells. In contrast, 
leptin exerts inhibitory effects on Th2 cells by reducing IgG1 
switching. On memory T cells, leptin promotes the switch 
towards Th1-cell immune responses by increasing IFN-γ and 
TNF secretion, the production of IgG2a by B cells and delayed-
type hypersensitivity (DTH) responses.48,55 As a survival 
factor, leptin has been shown to suppress B cell apoptosis (fi g 
4).5 
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Figure 4   Effects of leptin on innate and 
adaptive immune responses. In innate immunity, 
leptin modulates the activity and function of 
neutrophils by increasing chemotaxis and the 
secretion of oxygen radicals through direct 
and indirect mechanisms. Leptin increases 
phagocytosis by monocytes/macrophages and 
enhances the secretion of pro-infl ammatory 
mediators of the acute-phase response and 
the expression of adhesion molecules. On 
natural killer (NK) cells, leptin increases 
cytotoxic ability and the secretion of perforin 
and interleukin-2 (IL-2). In adaptive immunity, 
leptin affects the generation, maturation, and 
survival of thymic T cells by reducing their rate 
of apoptosis. On naive T-cell responses, leptin 
increases proliferation and IL-2 secretion. On 
memory T cells, leptin promotes the switch 
towards T helper (Th)1 -cell immune responses 
by increasing interferon-γ (IFN-γ) and TNF 
secretion. This process is then sustained by an 
autocrine loop of leptin secretion by Th1 cells. 
Leptin has anti-apoptotic effects on mature 
T cells and on haematopoietic precursors 
(adapted from La Cava et al., 2004).55
LEPTIN IN INFLAMMATION AND AUTOIMMUNITY
A growing body of evidence indicates that leptin acts as a pro-
infl ammatory cytokine in immune responses. Although pro-
infl ammatory factors are critical mediators of host defense 
mechanisms, these cytokines can negatively associate with 
the development of autoimmune diseases. Leptin has also 
been shown to enhance immune reactions in autoimmune 
diseases that are commonly associated with infl ammatory 
responses. Recent evidence indicates that leptin is involved 
in the dysregulated balance between Th1 and Th2 cytokines 
and contributes to the pathogenesis of RA. In contrast, leptin 
defi ciency has a protective effect on autoimmune diseases 
by altering the balance of Th1:Th2 cytokine production and 
promoting a Th2 response as shown in fasting RA patients 
exhibiting signifi cantly improved clinical disease activity 
correlated with a marked reduction in serum leptin and a shift 
toward Th2 cytokine production.5
 The immunomodulatory effects of leptin have also been 
linked to enhanced susceptibility to other autoimmune disease 
such as experimental autoimmune encephalomyelitis (EAE), 
a model of multiple sclerosis.67,68 Recent studies have shown 
that leptin is involved in the induction and progression of 
EAE.69,70 The ob/ob mice are resistant to EAE induction 
with increased IL-4 and a lack of IFN-γ after myelin-specifi c 
stimulation of T cells. Interestingly, leptin replacement renders 
these mice to become susceptible to the disease accompanied 
by a shift to Th1 type cytokine pattern and reversal of IgG1, 
a Th2 dependent antibody, to the Th1 dependent IgG2a.71 In 
both experimentally-induced colitis and hepatitis models, 
ob/ob mice exhibit a dramatic reduction of colitis severity 
along with reduced serum levels of TNF-α and IL-18.72 Leptin 
replacement converts disease resistance to susceptibility with 
spontaneous release of proinfl ammatory cytokines in these 
mice. The infl uence of leptin defi ciency has been examined on 
immune-mediated renal disease and accelerated nephrotoxic 
nephritis in the ob/ob mice which were found to be strongly 
protected from the disease.73
 Leptin is produced by adipocytes that are present in the 
perilymphonodal adipose tissue and the lymph node itself. In 
the lymph node, leptin promotes the differentiation of Th1 cells, 
the activation of monocytes/macrophages and the secretion of 
cytokines of the acute-phase response and oxygen radicals. 
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Figure 6   A model summarizing the 
reciprocal infl uence of leptin and sex 
hormones on the immune T cell function 
in females and males. Leptin might play 
a part in the prevalence of autoimmune 
conditions in females. The higher leptin 
levels in females are sustained by the 
reciprocal infl uence of estrogens on leptin 
secretion and the potentiation of leptin 
production by estrogens. In addition, APCs 
from females produce higher IL-12 than 
males. All these factors may contribute 
to the increased capacity of females to 
produce Th-1 pro-infl ammatory immune 
responses and therefore to the increased 
cell-mediated autoimmune disease 
susceptibility (adapted from Matarese et 
al., 2002).74
Autoantigens could be presented to Th0 cells that express the 
long form of the leptin receptor (OBRb). Leptin could then 
affect the priming of autoreactive T cells towards Th1-type 
pro-infl ammatory responses, for example, in experimentally 
induced autoimmune diseases that affect the central nervous 
system (CNS), the gastrointestinal mucosa, hepatocytes, 
pancreatic β-cells, synovial cells and cartilage. Paracrine 
effects of TH1 cells that produce leptin after activation with 
antigen could then sustain an autocrine loop of proliferation 
and T-cell survival (fi g 5).55,58 
 
In relation to the important role of leptin in autoimmunity, 
women have twice higher serum leptin levels than men adjusted 
for age and body mass index, and are predisposed to autoimmune 
diseases such as multiple sclerosis, rheumatoid arthritis, and 
SLE. Therefore, leptin might play a part in the prevalence of 
autoimmune conditions in females.1,5 The higher leptin levels 
in females are sustained by the reciprocal infl uence of estrogens 
on leptin secretion and the potentiation of leptin production by 
estrogens. In addition, APCs from females produce higher IL-
12 than males. All these factors may contribute to the increased 
capacity of females to produce Th-1 pro-infl ammatory 
immune responses and therefore to the increased cell-mediated 
autoimmune disease susceptibility (fi g 6).74 
Figure 5   A model for the role of leptin in 
autoimmunity. In the lymph node, leptin promotes 
the differentiation of T helper 1 (Th1) cells, 
the activation of monocytes/macrophages and 
the secretion of cytokines of the acute-phase 
response and oxygen radicals. Autoantigens could 
be presented to Th0 cells that express the long 
form of the leptin receptor (OBRb). Leptin could 
then affect the priming of autoreactive T cells 
towards Th1-type pro-infl ammatory responses. 
Leptin has autocrine effects on Th1 and paracrine 
effects on monocytes or macrophages leading 
to production of infl ammatory cytokines by those 
cells and fi nally leading to autoimmunity and 
tissue damage (adapted from La Cava et al., 
2004).55
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LEPTIN IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS
The role of leptin in the pathogenesis of SLE is not fully 
determined yet. A cross-sectional study done by Garcia-
Gonzales et al1 found that patients with SLE had higher serum 
leptin levels than those of the control group. A borderline 
negative correlation was observed between leptin levels and 
disease activity (MEX-SLEDAI score), but not statistically 
signifi cant (r = 0,3; p = 0,06). 
 Wislowska et al75 found that serum leptin levels in SLE 
patients with arthritis (p < 0,05) and CNS involvement (p = 
0,05) were signifi cantly lower in comparison with serum leptin 
levels in SLE patients without arthritis and CNS involvement. 
A positive correlation was found between serum leptin levels 
and the values of hemoglobin (r = 0,44; p < 0,02), but no 
correlation was found between serum leptin levels and the 
disease activity (SLEDAI score), nor between serum leptin 
levels and the disease damage index as measured by SLICC 
(Systemic Lupus International Collaborating Clinics). The 
serum leptin level was signifi cantly lower in SLE patients 
with the presence of arthritis or neurological disorders, which 
suggests that active chronic infl ammation may lower plasma 
leptin concentrations.
 Our study (see original article in this journal titled 
‘Correlation between serum leptin concentration and disease 
activity in normal body mass index premenopausal women 
with systemic lupus erythematosus’) found that the median of 
serum leptin levels in normal body mass index premenopausal 
women with SLE who had active disease (MEX-SLEDAI 
score greater than or equal to 2 points) was lower than that 
of patients with inactive disease (MEX-SLEDAI less than 2 
points), but this difference was not statistically signifi cant. A 
weak negative correlation was observed between serum leptin 
levels and MEX-SLEDAI score (r = -0,22; p = 0,07).
 Systemic lupus erythematosus is characterized by a 
predominantly humoral response (Th2 type) leading to over 
expression of Th2 cytokines, such as IL-4 and IL-10, whereas 
in rheumatoid arthritis is thought to be provoked by a more 
cellular response (Th1 type).76 Th2 immune responses lead 
to B cell hyperactivity and the production of pathogenic 
autoantibodies,6,7,8 which fi nally lead to tissue injury and 
damage.7 Leptin exerts inhibitory effects on Th2 cells,5 
leading to decreased production of IL-4 and IL-10 and then 
reduced activation of B cells. This circumstance may explain 
the discovery of the negative correlation between serum 
leptin levels and disease activity in several studies mentioned 
above. A scheme of hypothesis about the role of leptin in the 
pathogenesis of SLE (according to the author’s opinion) is 
shown in fi gure 7.
SUMMARY
Leptin has been recognized as a cytokine-like hormone with 
pleiotropic actions in modulating immune responses. The 
exact role of leptin in the pathogenesis of SLE is not fully 
determined yet. Systemic lupus erythematosus is characterized 
by a predominantly humoral response (Th2 type), leading 
to over expression of Th2 cytokines, such as IL-4 and IL-
10. Leptin has inhibitory effects on Th2 cells and may lead 
to decreased production of IL-4 and IL-10 and then reduced 
activation of B cells. Many studies are required to explore 
whether leptin has a protective effect or enhancement towards 
tissue injury and damage. 
Figure 7   Hypothesis of the role of 
leptin in the pathogenesis of systemic 
lupus erythematosus (SLE). The SLE 
is characterized by a predominantly 
humoral response (Th2 type), leading 
to over expression of Th2 cytokines, 
such as IL-4 and IL-10. Th2 immune 
responses lead to B cell hyperactivity 
and  the production of pathogenic 
autoantibodies, which fi nally lead to 
tissue injury and damage. Leptin has 
inhibitory effects on Th2 cells, leading 
to decreased production of IL-4 and 
IL-10 and then reduced activation of B 
cells and might have a protective effect 
on tissue injury and damage (author’s 
opinion).
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